Cargando…
Towards a global initiative for fibrosis treatment (GIFT)
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterised by increased scarring of lung tissue. Despite the recent introduction of novel drugs that slow disease progression, IPF remains a deadly disease, and the benefits of these new drugs differ markedly between patients. Huma...
Autores principales: | Molina-Molina, Maria, Agusti, Alvar, Crestani, Bruno, Schwartz, David A., Königshoff, Melanie, Chambers, Rachel C., Maher, Toby M., Faner, Rosa, Mora, Ana Lucia, Rojas, Mauricio, Antoniou, Katerina M., Sellares, Jacobo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710382/ https://www.ncbi.nlm.nih.gov/pubmed/29214157 http://dx.doi.org/10.1183/23120541.00106-2017 |
Ejemplares similares
-
Cellular Senescence in Lung Fibrosis
por: Hernandez-Gonzalez, Fernanda, et al.
Publicado: (2021) -
Lung immune signatures define two groups of end-stage IPF patients
por: Cruz, Tamara, et al.
Publicado: (2023) -
Blood Immunophenotypes of Idiopathic Pulmonary Fibrosis: Relationship with Disease Severity and Progression
por: Mendoza, Nuria, et al.
Publicado: (2023) -
On Gifts and Heroes
por: Kolbe, Laura
Publicado: (2021) -
Persistence of a SARS-CoV-2 T-cell response in patients with long COVID and lung sequelae after COVID-19
por: Cruz, Tamara, et al.
Publicado: (2023)